Clazosentan failed to meet the primary endpoint of preventing clinical deterioration as a result of delayed cerebral ischemia (DCI) in patients with aneurysmal subarachnoid hemorrhage (aSAH), ...
BOULDER, Colo., Jan. 11, 2012 /PRNewswire/ -- Clarimedix, Inc., a privately held company focused on the development of non-invasive therapeutics for the treatment of disorders associated with vascular ...
YOKNEAM, Israel & MIAMI--(BUSINESS WIRE)--Rapid Medical, a leading developer of advanced neurovascular devices, today announced FDA breakthrough designation for its Comaneci™ embolization assist ...
The new device will interact with the nerves responsible for constriction of brain arteries - a common complication after hemorrhagic stroke GENEVA--(BUSINESS WIRE)--The Wyss Center and Artiria ...
Please provide your email address to receive an email when new articles are posted on . Moderate to severe angiographic vasospasm was detected more often in controls than in those given implants. At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results